195 related articles for article (PubMed ID: 18594210)
1. Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.
Cavalloni G; Sarotto I; Pignochino Y; Gammaitoni L; Migliardi G; Sgro L; Piacibello W; Risio M; Aglietta M; Leone F
Anticancer Drugs; 2008 Aug; 19(7):689-96. PubMed ID: 18594210
[TBL] [Abstract][Full Text] [Related]
2. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
4. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
5. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
Kim WE; Serrero G
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
[TBL] [Abstract][Full Text] [Related]
6. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
7. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
9. Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration.
Morales-Arias J; Meyers PA; Bolontrade MF; Rodriguez N; Zhou Z; Reddy K; Chou AJ; Koshkina NV; Kleinerman ES
Cancer; 2007 Oct; 110(7):1568-77. PubMed ID: 17694551
[TBL] [Abstract][Full Text] [Related]
10. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
[TBL] [Abstract][Full Text] [Related]
11. Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on lung cancer: roles of cyclooxygenase-2.
Uemura Y; Kobayashi M; Nakata H; Kubota T; Saito T; Bandobashi K; Taguchi H
Oncol Rep; 2007 Apr; 17(4):955-61. PubMed ID: 17342342
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells.
Fujita T; Doihara H; Washio K; Kawasaki K; Takabatake D; Takahashi H; Tsukuda K; Ogasawara Y; Shimizu N
Anticancer Drugs; 2006 Apr; 17(4):455-62. PubMed ID: 16550004
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.
Pályi-Krekk Z; Barok M; Isola J; Tammi M; Szöllosi J; Nagy P
Eur J Cancer; 2007 Nov; 43(16):2423-33. PubMed ID: 17911008
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells.
Chakraborty A; Guha S
Urology; 2007 Jun; 69(6):1210-5. PubMed ID: 17572226
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
[TBL] [Abstract][Full Text] [Related]
18. Additive effects of trastuzumab and genistein on human breast cancer cells.
Lattrich C; Lubig J; Springwald A; Goerse R; Ortmann O; Treeck O
Anticancer Drugs; 2011 Mar; 22(3):253-61. PubMed ID: 21160418
[TBL] [Abstract][Full Text] [Related]
19. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression.
Henson ES; Hu X; Gibson SB
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):845-53. PubMed ID: 16467098
[TBL] [Abstract][Full Text] [Related]
20. Solamargine enhances HER2 expression and increases the susceptibility of human lung cancer H661 and H69 cells to trastuzumab and epirubicin.
Liang CH; Shiu LY; Chang LC; Sheu HM; Tsai EM; Kuo KW
Chem Res Toxicol; 2008 Feb; 21(2):393-9. PubMed ID: 18078328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
